European Journal of Clinical Pharmacology

, Volume 73, Issue 10, pp 1287–1295 | Cite as

Adverse cardiac events associated with incident opioid drug use among older adults with COPD

  • Nicholas T. Vozoris
  • Xuesong Wang
  • Peter C. Austin
  • Douglas S. Lee
  • Anne L. Stephenson
  • Denis E. O’Donnell
  • Sudeep S. Gill
  • Paula A. Rochon
Pharmacoepidemiology and Prescription

Abstract

Purpose

We evaluated whether incident opioid drug use was associated with adverse cardiac events among older adults with chronic obstructive pulmonary disease (COPD).

Methods

This was an exploratory, retrospective cohort study using health administrative data from Ontario, Canada, from 2008 to 2013. Using a validated algorithm, we identified adults aged 66 years and older with non-palliative COPD. Hazard ratios (HR) were estimated for adverse cardiac events within 30 days of incident opioid receipt compared to controls using inverse probability of treatment weighting using the propensity score.

Results

There were 134,408 community-dwelling individuals and 14,685 long-term care residents with COPD identified, 67.0 and 60.6% of whom received an incident opioid. Incident use of any opioid was associated with significantly decreased rates of emergency room (ER) visits and hospitalizations for congestive heart failure (CHF) among community-dwelling older adults (HR 0.84; 95% CI 0.73–0.97), but significantly increased rates of ischemic heart disease (IHD)-related mortality among long-term care residents (HR 2.15; 95% CI 1.50–3.09). In the community-dwelling group, users of more potent opioid-only agents without aspirin or acetaminophen combined had significantly increased rates of ER visits and hospitalizations for IHD (HR 1.38; 95% CI 1.08–1.77) and IHD-related mortality (HR 1.83; 95% CI 1.32–2.53).

Conclusions

New opioid use was associated with elevated rates of IHD-related morbidity and mortality among older adults with COPD. Adverse cardiac events may need to be considered when administering new opioids to older adults with COPD, but further studies are required to establish if the observed associations are causal or related to residual confounding.

Keywords

Opioids COPD Cardiac Pharmacoepidemiology Drug safety 

Notes

Authors’ contributions

NTV, XW, PAC, DSL, ALS, DEO, SSG and PAR contributed substantially to the study design, data analysis and interpretation and the writing of the manuscript.

Compliance with ethical standards

This study was approved by the review ethics board at Sunnybrook Health Sciences Centre.

Conflicts of interest

All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare the following: NTV had support from Godfrey S. Pettit Respirology Block Term Grant for the submitted work; XW, PAC, DSL, ALS, DEO, SSG and PAR had no support from any organization for the submitted work; DEO received grants and personal fees from Boehringer Ingelheim, grants and personal fees from Astra Zeneca, grants from GlaxoSmithKline and personal fees from Novartis, in the previous 3 years; NTV, XW, PAC, DSL, ALS, DEO, SSG and PAR had no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; and NTV, XW, PAC, DSL, ALS, DEO, SSG and PAR had no other relationships or activities that could appear to have influenced the submitted work.

Funding

This research was funded by a Godfrey S. Pettit Respirology Block Term Grant. This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI. Parts of this material are based on data and information provided by Cancer Care Ontario (CCO). The opinions, results, view and conclusions reported in this paper are those of the authors and do not necessarily reflect those of CCO. No endorsement by CCO is intended or should be inferred. We thank Brogan Inc., Ottawa for use of their Drug Information Database. P.C. Austin was supported in part by a Career Investigator Award from the Heart and Stroke Foundation. D.S. Lee was supported by a mid-career investigator award from the Heart and Stroke Foundation and is the Ted Rogers Chair in Heart Function Outcomes.

Supplementary material

228_2017_2278_MOESM1_ESM.doc (649 kb)
ESM 1 (DOC 649 kb)

References

  1. 1.
    Vozoris NT, Wang X, Fischer HD, Gershon AS, Bell CM, Gill SS et al (2016) Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol 81:161–170CrossRefPubMedGoogle Scholar
  2. 2.
    Ahmadi Z, Bernelid E, Currow DC, Ekstrom M (2016) Prescription of opioids for breathlessness in end-stage COPD: a national population-based study. Int J Chron Obstruct Pulmon Dis 11:2651–2657CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Huiart L, Ernst P, Suissa S (2005) Cardiovascular morbidity and mortality in COPD. Chest 128:2640–2646CrossRefPubMedGoogle Scholar
  4. 4.
    Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr et al (2006) Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada. Ann Epidemiol 16:63–70CrossRefPubMedGoogle Scholar
  5. 5.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, TORCH investigators et al (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–789CrossRefPubMedGoogle Scholar
  6. 6.
    Schultz JE, Rose E, Yao Z, Gross GJ (1995) Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Phys 268:H2157–H2161Google Scholar
  7. 7.
    Chien GL, Van Winkle DM (1996) Naloxone blockade of myocardial ischemic preconditioning is stereoselective. J Mol Cell Cardiol 28:1895–1900CrossRefPubMedGoogle Scholar
  8. 8.
    Okubo S, Tanabe Y, Takeda K, Kitayama M, Kanemitsu S, Kukreja RC et al (2004) Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits: role of delta-opioid receptor. Am J Physiol Heart Circ Physiol 287:H1786–H1791CrossRefPubMedGoogle Scholar
  9. 9.
    Pinsky MR (2002) Recent advances in the clinical application of heart-lung interactions. Curr Opin Crit Care 8:26–31CrossRefPubMedGoogle Scholar
  10. 10.
    Sonntag H, Larsen R, Hilfiker O, Kettler D, Brockschnieder B (1982) Myocardial blood flow and oxygen consumption during high-dose fentanyl anesthesia in patients with coronary artery disease. Anesthesiology 56:417–422CrossRefPubMedGoogle Scholar
  11. 11.
    Jennings DB, Sparling J (1974) Effects of low O2 and high CO2 on cardiorespiratory function in conscious resting dogs. Am J Phys 226:431–438Google Scholar
  12. 12.
    Asgary S, Sarrafzadegan N, Naderi GA, Rozbehani R (2008) Effect of opium addiction on new and traditional cardiovascular risk factors: do duration of addiction and route of administration matter? Lipids Health Dis 7:42CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Masoudkabir F, Sarrafzadegan N, Eisenberg MJ (2013) Effects of opium consumption on cardiometabolic diseases. Nat Rev Cardiol 10:733–740CrossRefPubMedGoogle Scholar
  14. 14.
    Carman WJ, Su S, Cook SF, Wurzelmann JI, McAfee A (2011) Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf 20:754–762CrossRefPubMedGoogle Scholar
  15. 15.
    Li L, Setoguchi S, Cabral H, Jick S (2013) Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med 273:511–526CrossRefPubMedGoogle Scholar
  16. 16.
    Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2016) Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA 315:2415–2423CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE (2002) A systematic review of the use of opioids in the management of dyspnoea. Thorax 57:939–944CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C (2003) Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 327:523–528CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P et al (2011) Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manag 42:388–399CrossRefGoogle Scholar
  20. 20.
    Rocker GM, Simpson AC, Young J, Horton R, Sinuff T, Demmons J et al (2013) Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients’ experiences and outcomes. CMAJ Open 1:E27–E36CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T (2009) Identifying individuals with physician diagnosed COPD in health administrative databases. J COPD 6:388–394CrossRefGoogle Scholar
  22. 22.
    Levy R, O’Brien BJ, Sellors C, Grootendorst P, Willison D (2003) Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10:67–71PubMedGoogle Scholar
  23. 23.
    Gershon AS, Wang C, Wilton AS, Raut R, To T (2010) Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med 170:560–565CrossRefPubMedGoogle Scholar
  24. 24.
    Vozoris NT, Fischer HD, Wang X, Stephenson AL, Gershon AS, Gruneir A et al (2014) Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 44:332–340CrossRefPubMedGoogle Scholar
  25. 25.
    Vozoris NT, Wang X, Fischer HD, Bell CM, O’Donnell DE, Austin PC et al (2016) Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 48:683–693CrossRefPubMedGoogle Scholar
  26. 26.
    Tu K, Mitiku T, Lee DS, Guo H, Tu JV (2010) Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD). Can J Cardiol 26:e225–e228CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Schultz SE, Rothwell DM, Chen Z, Tu K (2013) Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 33:160–166PubMedGoogle Scholar
  28. 28.
    Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399–424CrossRefGoogle Scholar
  29. 29.
    Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34:3661–3679CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Eidelman RS, Hebert PR, Weisman SM, Hennekens CH (2003) An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163:2006–2010CrossRefPubMedGoogle Scholar
  31. 31.
    Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57:847–852CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Spencer S, Calverley PM, Burge PS, Jones PW (2004) Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 23:698–702CrossRefPubMedGoogle Scholar
  33. 33.
    Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128–1138CrossRefPubMedGoogle Scholar
  34. 34.
    Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ et al (1996) Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 154:959–967CrossRefPubMedGoogle Scholar
  35. 35.
    O’Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D et al (2008) Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2008 update—highlights for primary care. Can Respir J 15S:1A–8AGoogle Scholar
  36. 36.
    Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016 (Accessed October 2016).Google Scholar
  37. 37.
    Wen SW, Hernandez R, Naylor CD (1995) Pitfalls in nonrandomized outcomes studies. The case of incidental appendectomy with open cholecystectomy. JAMA 274:1687–1691CrossRefPubMedGoogle Scholar
  38. 38.
    Austin PC (2013) The performance of different propensity-score methods for estimating marginal hazard ratios. Stat Med 32:2837–2849CrossRefPubMedGoogle Scholar
  39. 39.
    Argoff CE, Silvershein DI (2009) A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc 84:602–612CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Nicholas T. Vozoris
    • 1
    • 2
    • 3
  • Xuesong Wang
    • 4
  • Peter C. Austin
    • 4
    • 5
  • Douglas S. Lee
    • 3
    • 4
    • 5
  • Anne L. Stephenson
    • 1
    • 2
    • 3
    • 5
  • Denis E. O’Donnell
    • 6
  • Sudeep S. Gill
    • 4
    • 6
  • Paula A. Rochon
    • 3
    • 4
    • 5
    • 7
  1. 1.Division of Respirology, Department of MedicineSt. Michael’s HospitalTorontoCanada
  2. 2.Keenan Research Centre in the Li Ka Shing Knowledge InstituteSt. Michael’s HospitalTorontoCanada
  3. 3.Department of MedicineUniversity of TorontoTorontoCanada
  4. 4.Institute for Clinical Evaluative SciencesTorontoCanada
  5. 5.Institute of Health Policy, Management and EvaluationUniversity of TorontoTorontoCanada
  6. 6.Department of MedicineQueen’s UniversityKingstonCanada
  7. 7.Women’s College Research InstituteWomen’s College HospitalTorontoCanada

Personalised recommendations